ZA9810743B - Inhibition of lipoprotein oxidation - Google Patents
Inhibition of lipoprotein oxidationInfo
- Publication number
- ZA9810743B ZA9810743B ZA9810743A ZA9810743A ZA9810743B ZA 9810743 B ZA9810743 B ZA 9810743B ZA 9810743 A ZA9810743 A ZA 9810743A ZA 9810743 A ZA9810743 A ZA 9810743A ZA 9810743 B ZA9810743 B ZA 9810743B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibition
- lipoprotein oxidation
- lipoprotein
- oxidation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6688897P | 1997-11-25 | 1997-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA9810743B true ZA9810743B (en) | 1999-05-31 |
Family
ID=22072341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9810743A ZA9810743B (en) | 1997-11-25 | 1998-11-24 | Inhibition of lipoprotein oxidation |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6362236B1 (es) |
| EP (1) | EP1047421A2 (es) |
| JP (1) | JP2001523694A (es) |
| KR (3) | KR20050086975A (es) |
| CN (1) | CN1160068C (es) |
| AR (1) | AR015487A1 (es) |
| AU (1) | AU759376B2 (es) |
| BR (1) | BR9815039A (es) |
| CA (1) | CA2303864A1 (es) |
| CO (1) | CO4970835A1 (es) |
| HK (1) | HK1033095A1 (es) |
| HU (1) | HUP0004396A3 (es) |
| IL (1) | IL135154A (es) |
| IS (1) | IS5413A (es) |
| NO (1) | NO20002639L (es) |
| NZ (1) | NZ503598A (es) |
| PE (1) | PE134199A1 (es) |
| PL (1) | PL341397A1 (es) |
| TR (1) | TR200001522T2 (es) |
| TW (1) | TW552137B (es) |
| UY (1) | UY25268A1 (es) |
| WO (1) | WO1999026583A2 (es) |
| ZA (1) | ZA9810743B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7250304B2 (en) * | 2000-03-31 | 2007-07-31 | The Regents Of The University Of California | Functional assay of high-density lipoprotein |
| US20030040505A1 (en) * | 2000-03-31 | 2003-02-27 | The Regents Of The University Of California | Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
| US20030114497A1 (en) * | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
| SI2404890T1 (sl) | 2003-01-23 | 2017-12-29 | Esperion Therapeutics Inc. | Hidroksilne spojine in sestavki za uravnavanje holesterola in sorodne uporabe |
| US20060194981A1 (en) * | 2005-02-26 | 2006-08-31 | Jass Paul A | Process for preparation of probucol derivatives |
| WO2006104399A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
| EP3578177A1 (en) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| RU2538691C2 (ru) | 2009-04-29 | 2015-01-10 | Амарин Фарма, Инк. | Стабильные фармацевтические композиции и способы их применения |
| EP3563842A1 (en) | 2009-04-29 | 2019-11-06 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| LT3318255T (lt) | 2009-06-15 | 2021-05-25 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti insulto gydymui pacientui kartu su statinų terapija |
| CA2775339C (en) | 2009-09-23 | 2017-03-28 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| EP4342546A3 (en) | 2012-06-29 | 2024-05-22 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| KR101665180B1 (ko) | 2014-07-01 | 2016-10-14 | 순천향대학교 산학협력단 | 아포지단백질 a-i 돌연변이체 g59v를 포함하는 항산화성 펩타이드 및 이를 포함하는 항산화 조성물 |
| MX2017011499A (es) | 2015-03-13 | 2018-03-26 | Esperion Therapeutics Inc | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| FI4056176T3 (fi) | 2018-09-24 | 2024-05-30 | Amarin Pharmaceuticals Ie Ltd | Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa |
| KR20220024816A (ko) | 2019-06-21 | 2022-03-03 | 에스페리온 테라피유틱스 인코포레이티드 | 벰페도산 및 그의 조성물을 제조하는 방법 |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385929A (en) * | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
-
1998
- 1998-11-04 EP EP98959378A patent/EP1047421A2/en not_active Withdrawn
- 1998-11-04 HU HU0004396A patent/HUP0004396A3/hu unknown
- 1998-11-04 PL PL98341397A patent/PL341397A1/xx not_active Application Discontinuation
- 1998-11-04 US US09/485,250 patent/US6362236B1/en not_active Expired - Fee Related
- 1998-11-04 KR KR1020057014824A patent/KR20050086975A/ko not_active Application Discontinuation
- 1998-11-04 CA CA002303864A patent/CA2303864A1/en not_active Abandoned
- 1998-11-04 IL IL13515498A patent/IL135154A/xx not_active IP Right Cessation
- 1998-11-04 WO PCT/US1998/023483 patent/WO1999026583A2/en not_active Application Discontinuation
- 1998-11-04 BR BR9815039-1A patent/BR9815039A/pt not_active Application Discontinuation
- 1998-11-04 AU AU15188/99A patent/AU759376B2/en not_active Ceased
- 1998-11-04 JP JP2000521788A patent/JP2001523694A/ja not_active Abandoned
- 1998-11-04 KR KR10-2000-7005641A patent/KR100539644B1/ko not_active IP Right Cessation
- 1998-11-04 CN CNB988112671A patent/CN1160068C/zh not_active Expired - Fee Related
- 1998-11-04 TR TR2000/01522T patent/TR200001522T2/xx unknown
- 1998-11-04 KR KR1020057021847A patent/KR100586754B1/ko not_active IP Right Cessation
- 1998-11-04 NZ NZ503598A patent/NZ503598A/en unknown
- 1998-11-24 ZA ZA9810743A patent/ZA9810743B/xx unknown
- 1998-11-24 CO CO98069227A patent/CO4970835A1/es unknown
- 1998-11-24 AR ARP980105959A patent/AR015487A1/es unknown
- 1998-11-24 UY UY25268A patent/UY25268A1/es not_active Application Discontinuation
- 1998-11-24 PE PE1998001143A patent/PE134199A1/es not_active Application Discontinuation
- 1998-11-25 TW TW087119590A patent/TW552137B/zh not_active IP Right Cessation
-
2000
- 2000-03-24 IS IS5413A patent/IS5413A/is unknown
- 2000-05-23 NO NO20002639A patent/NO20002639L/no unknown
-
2001
- 2001-06-04 HK HK01103822A patent/HK1033095A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1033095A1 (en) | 2001-08-17 |
| UY25268A1 (es) | 1999-07-19 |
| KR100539644B1 (ko) | 2005-12-29 |
| HUP0004396A2 (hu) | 2001-06-28 |
| WO1999026583A3 (en) | 1999-12-09 |
| IS5413A (is) | 2000-03-24 |
| PE134199A1 (es) | 2000-01-20 |
| NZ503598A (en) | 2002-06-28 |
| WO1999026583A2 (en) | 1999-06-03 |
| KR20050113288A (ko) | 2005-12-01 |
| TR200001522T2 (tr) | 2000-12-21 |
| BR9815039A (pt) | 2001-03-20 |
| CA2303864A1 (en) | 1999-06-03 |
| KR20050086975A (ko) | 2005-08-30 |
| KR20010032401A (ko) | 2001-04-16 |
| AU759376B2 (en) | 2003-04-10 |
| AR015487A1 (es) | 2001-05-02 |
| JP2001523694A (ja) | 2001-11-27 |
| HUP0004396A3 (en) | 2003-04-28 |
| CN1160068C (zh) | 2004-08-04 |
| NO20002639D0 (no) | 2000-05-23 |
| CN1279605A (zh) | 2001-01-10 |
| IL135154A0 (en) | 2001-05-20 |
| CO4970835A1 (es) | 2000-11-07 |
| IL135154A (en) | 2005-05-17 |
| KR100586754B1 (ko) | 2006-06-08 |
| PL341397A1 (en) | 2001-04-09 |
| TW552137B (en) | 2003-09-11 |
| US6362236B1 (en) | 2002-03-26 |
| AU1518899A (en) | 1999-06-15 |
| NO20002639L (no) | 2000-05-23 |
| EP1047421A2 (en) | 2000-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL135154A0 (en) | Inhibition of lipoprotein oxidation | |
| PL339551A1 (en) | Derivatives of rezorcin | |
| PL334846A1 (en) | Sulphamidic inhibitors of metaloproteases | |
| PL337827A1 (en) | Bactericidal derivatives of n-sulphoglycin alkynyloxyphenethylamide | |
| PL347029A1 (en) | Reduction of oxidative stress factors | |
| SG71785A1 (en) | Deploymerization of polyamides | |
| EP1039914A4 (en) | CYCLOOXYGENASE-2 INHIBITION | |
| HU9702480D0 (en) | New polymorphe modification of doxazosin-mesylate | |
| PL334769A1 (en) | Derivatives of 5-aroylnaphtene | |
| HU9702479D0 (en) | New polymorphe modification of doxazosin-mesylate | |
| AU5200699A (en) | Inhibition of lipoprotein formation | |
| EP0981545A4 (en) | TREATMENT OF OSTEOPOROSIS | |
| PL338777A1 (en) | Derivative of piperidinylmethyloxazolydinone | |
| ZA985064B (en) | Derivatives of pentaerythrits | |
| GB9706285D0 (en) | Means of assembly | |
| PL317319A1 (en) | Oxidative amonolysis of alkylopyridines | |
| PL334066A1 (en) | Oily composition of dihydropolyprenoles | |
| PL325816A1 (en) | Novel derivatives of naphtylpiperazine | |
| PL313849A1 (en) | Beta-aminoesters of o-hydrobenzylamides | |
| PL319263A1 (en) | Novel derivative of pyrimidinylcarbazole | |
| PL327430A1 (en) | Set of shaped components | |
| TW312301U (en) | Improved structure of earmask | |
| TW319017U (en) | Improved structure of mousetraps | |
| GB9722026D0 (en) | Use of compounds | |
| TW357554U (en) | Improvement of shinguards |